BergenstalRM, KlonoffDC, GargSK, et al.: Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med, 2013; 369:224–232.
2.
KropffJ, DeVriesJH: Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects. Diabetes Technol Ther, 2016; 18Suppl 2:S253–S263.
3.
HovorkaR, ElleriD, ThabitH, et al.: Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care, 2014; 37:1204–1211.
4.
ThabitH, Lubina-SolomonA, StadlerM, et al.: Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol, 2014; 2:701–709.
5.
ThabitH, ElleriD, LeelarathnaL, et al.: Unsupervised home use of an overnight closed-loop system over 3–4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab, 2015; 17:452–458.
6.
BergenstalRM, GargS, WeinzimerSA, et al.: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016; 316:1407–1408.
7.
TilleskjorS. Breaking news: FDA approves the MiniMed 670G System, World's First Hybrid Closed Loop System. 2016. www.medtronicdiabetes.com/blog/introducing-the-minimed-670g-system (accessed November29, 2016).
8.
KovatchevB, ChengP, AndersonSM, et al.: Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther, 2017; 19:18–24.
9.
ForlenzaGP, SankaranarayananS, MaahsDM: Refining the closed loop in the data age: research-to-practice transitions in diabetes technology. Diabetes Technol Ther, 2015; 17:304–306.
10.
BarnardKD, HoodKK, Weissberg-BenchellJ, et al.: Psychosocial assessment of artificial pancreas (AP): commentary and review of existing measures and their applicability in AP research. Diabetes Technol Ther, 2015; 17:295–300.
11.
LibermanA, BuckinghamB: Diabetes technology and the human factor. Diabetes Technol Ther, 2016; 18Suppl 1:S101–S111.
12.
NaranjoD, TanenbaumML, IturraldeE, et al.: Diabetes technology: uptake, outcomes, barriers, and the intersection with distress. J Diabetes Sci Technol, 2016; 10:852–858.
13.
MaahsDM, BuckinghamBA, CastleJR, et al.: Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care, 2016; 39:1175–1179.
14.
RussellSJ, BeckRW: Design considerations for artificial pancreas pivotal studies. Diabetes Care, 2016; 39:1161–1167.
15.
LewisD: What is #OpenAPS?. 2016. https://OpenAPS.org (accessed November29, 2016).
16.
KowalskiA: Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care, 2015; 38:1036–1043.
17.
BlauwH, van BonAC, KoopsR, et al.: Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab, 2016; 18:671–677.
18.
HaidarA, Rabasa-LhoretR, LegaultL, et al.: Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes. J Clin Endocrinol Metab, 2016; 101:214–223.
19.
RussellSJ, El-KhatibFH, SinhaM, et al.: Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med, 2014; 371:313–325.
20.
LyTT, BretonMD, Keith-HynesP, et al.: Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care, 2014; 37:2310–2316.
21.
NimriR, MullerI, AtlasE, et al.: MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care, 2014; 37:3025–3032.
22.
Del FaveroS, BoscariF, MessoriM, et al.: Randomized summer camp crossover trial in 5- to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care, 2016; 39:1180–1185.
23.
RussellSJ, HillardMA, BalliroC, et al.: Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol, 2016; 4:233–243.
